<DOC>
	<DOCNO>NCT02946632</DOCNO>
	<brief_summary>In study , investigator assess efficacy tolerability novel , initial triple combination therapy metformin , saxaglipitin , dapagliflozin , compare conventional stepwise add-on therapy drug-naïve patient recently onset type 2 diabetes .</brief_summary>
	<brief_title>Effectiveness &amp; Tolerability Novel , Initial Triple Combination Therapy vs Conventional Therapy Type 2 Diabetes</brief_title>
	<detailed_description>ADA/EASD guideline recommend sequential treatment approach start metformin , add class anti-diabetic medication target HbA1c achieve . However , several clinical study clearly show initial dual triple combination therapy favorable term glycemic control . A DPP-4 inhibitor saxagliptin increase serum level GLP-1 , potentiate action increase glucose-dependent insulin secretion lower glucagon secretion . A SGLT-2 inhibitor dapagliflozin lower hyperglycemia via block SGLT-2 increase glucosuria , , insulin-independent manner . Therefore , mechanism action drug complimentary metformin , low risk hypoglycemia weight gain .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Drugnaïve patient type 2 diabetes American Diabetes Association criterion HbA1c ≥ 8 % , &lt; 10.5 % screening Age ≥ 18 year , &lt; 65 year Body mass index ( BMI ) ≥ 23 kg/m2 , &lt; 35 kg/m2 Estimated GFR ( eGFR ) ≥ 60 ml/min/1.73m2 Uncontrolled hyperglycemia &gt; 270 mg/dl overnight fast Diabetic ketoacidosis Type 1 diabetes Confirmed cardiovascular disease ( acute coronary syndrome , stroke , transient ischemic attack ) within 3 month screen Congestive heart failure ( New York Heart Association functional class IV ) severe hepatic dysfunction ( serum level either AST , ALT , alkaline phosphatase 3 x upper limit normal ( ULN ) ) alcohol abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake pregnant woman , woman potential pregnancy use adequate contraception method evaluate investigator , lactate woman use systemic glucocorticoid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>